Mergers and Acquisitions Acquisitions Real Estate Transactions Real Estate Investments Company Sales Divestment Stake Acquisitions Asset Sales Pharmaceutical Companies Equity Purchase Agreements
Adaptimmune retains its two preclinical T cell therapies after selling Tecelra plus two clinical-stage programs in a $55 million deal that shifts commercialization staff to U.S. WorldMeds.